It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APM’s FA Score shows that 2 FA rating(s) are green whileBMNDF’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APM’s TA Score shows that 6 TA indicator(s) are bullish while BMNDF’s TA Score has 1 bullish TA indicator(s).
APM (@Biotechnology) experienced а -17.27% price change this week, while BMNDF (@Biotechnology) price change was +127.57% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.
APM is expected to report earnings on Apr 28, 2023.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
APM | BMNDF | APM / BMNDF | |
Capitalization | 8.22M | 16.2M | 51% |
EBITDA | -9.6M | -314.15K | 3,056% |
Gain YTD | -58.929 | 127.568 | -46% |
P/E Ratio | 3.71 | N/A | - |
Revenue | 431K | 0 | - |
Total Cash | 2.01M | 10.1K | 19,851% |
Total Debt | 3.28M | 883K | 372% |
APM | BMNDF | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 29 Undervalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 61 | |
SMR RATING 1..100 | 94 | 100 | |
PRICE GROWTH RATING 1..100 | 53 | 34 | |
P/E GROWTH RATING 1..100 | 17 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
APM's Valuation (29) in the Pharmaceuticals Major industry is significantly better than the same rating for BMNDF (96) in the null industry. This means that APM’s stock grew significantly faster than BMNDF’s over the last 12 months.
BMNDF's Profit vs Risk Rating (61) in the null industry is somewhat better than the same rating for APM (100) in the Pharmaceuticals Major industry. This means that BMNDF’s stock grew somewhat faster than APM’s over the last 12 months.
APM's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as BMNDF (100) in the null industry. This means that APM’s stock grew similarly to BMNDF’s over the last 12 months.
BMNDF's Price Growth Rating (34) in the null industry is in the same range as APM (53) in the Pharmaceuticals Major industry. This means that BMNDF’s stock grew similarly to APM’s over the last 12 months.
APM's P/E Growth Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for BMNDF (100) in the null industry. This means that APM’s stock grew significantly faster than BMNDF’s over the last 12 months.
APM | BMNDF | |
---|---|---|
RSI ODDS (%) | 11 days ago89% | N/A |
Stochastic ODDS (%) | 11 days ago79% | N/A |
Momentum ODDS (%) | 11 days ago85% | N/A |
MACD ODDS (%) | N/A | N/A |
TrendWeek ODDS (%) | 11 days ago90% | 11 days ago41% |
TrendMonth ODDS (%) | 11 days ago77% | 11 days ago42% |
Advances ODDS (%) | 19 days ago80% | N/A |
Declines ODDS (%) | 11 days ago90% | N/A |
BollingerBands ODDS (%) | 11 days ago90% | N/A |
Aroon ODDS (%) | 11 days ago74% | 11 days ago72% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MACGX | 15.42 | 0.24 | +1.58% |
Morgan Stanley Inst Discovery A | |||
IYCEX | 17.26 | 0.16 | +0.94% |
Macquarie Core Equity Fund Class R | |||
IGIVX | 101.83 | 0.93 | +0.92% |
Integrity Growth & Income Fund I | |||
RICGX | 58.93 | 0.51 | +0.87% |
American Funds Invmt Co of Amer R6 | |||
APSRX | 17.19 | 0.04 | +0.23% |
NYLI Fiera SMID Growth Class A |
A.I.dvisor tells us that BMNDF and APM have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BMNDF and APM's prices will move in lockstep.
Ticker / NAME | Correlation To BMNDF | 1D Price Change % | ||
---|---|---|---|---|
BMNDF | 100% | N/A | ||
APM - BMNDF | 27% Poorly correlated | -3.36% | ||
LVTX - BMNDF | 23% Poorly correlated | +0.06% | ||
PHGE - BMNDF | 22% Poorly correlated | +0.95% | ||
NKGN - BMNDF | 20% Poorly correlated | -4.43% | ||
CYDY - BMNDF | 12% Poorly correlated | +1.31% | ||
More |